Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B2OC
|
|||
| Former ID |
DCL000968
|
|||
| Drug Name |
R-sibutramine metabolite
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] | Discontinued in Phase 2 | [1] | |
| Depression [ICD-11: 6A70-6A7Z] | Discontinued in Phase 2 | [1] | ||
| Company |
Sepracor
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Norepinephrine transporter (NET) | Target Info | Modulator | [2] |
| Serotonin transporter (SERT) | Target Info | Modulator | [2] | |
| KEGG Pathway | Serotonergic synapse | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | ||||
| 5HT3 type receptor mediated signaling pathway | ||||
| 5HT4 type receptor mediated signaling pathway | ||||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| SIDS Susceptibility Pathways | ||||
| Synaptic Vesicle Pathway | ||||
| Serotonin Transporter Activity | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. | |||
| REF 2 | Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.Eur J Pharmacol.2014 Aug 15;737:47-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.